This article was originally published in The Tan Sheet
Executive SummaryFDA clarifies the comment period regarding behind-the-counter availability of some nonprescription drugs continues through Dec. 17, the agency says in a Nov. 27 Federal Register notice. The docket for comments on the topic will remain open for 30 days following the meeting FDA conducted Nov. 14 to obtain comments on BTC availability, but in its Oct. 4 notice announcing the meeting, the agency incorrectly listed the deadline as Nov. 28....
You may also be interested in...
The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.